Welcome to TDR’s review of the Top 5 Psychedelic Developments for the week of July 24. Aside from presenting a synopsis of events, we provide
The influenza (flu) virus is constantly undergoing a process of evolution and adaptation through acquiring new mutations.
The Journal of Pediatrics has published a manuscript by Stacey Martiniano, MD, pulmonary specialist at Children’s Hospital Colorado and associate professor of pediatrics at the
A novel testing platform under development by researchers at the Yale School of Public Health (YSPH) and CytoAstra, LLC could provide a new noninvasive test
Big Pharma companies are catching the artificial intelligence wave, evidenced by a number of drugmakers’ comments in their half-year earnings reports this week. A handful
Republican lawmakers released a draft of a new bill that aims to stem drug shortages after Republicans in the House Energy and Commerce Committee blocked efforts
Merck’s blockbuster anti-PD-1 therapy Keytruda is inching its way toward another potential indication, this time a chemotherapy combo pre-surgery in patients with high-risk, early-stage ER+/HER2-
Siga Technologies said Thursday that the US has ordered $113 million of the company’s oral Tpoxx treatment courses and $25 million of the intravenous version
The first six months of a drug launch are critical to its success. But pharma marketers can boost its chances with the addition of medical
Sanofi and BioNTech scrapped development of an mRNA therapy that can be injected into a tumor after seeing results from an interim analysis. Sanofi on